CEFTAZIDIME AVIBACTAM MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2025 - 2032)

Global Ceftazidime Avibactam Market Size and Forecast – 2025 to 2032

The global ceftazidime avibactam market is estimated to be valued at USD 3.43 Bn in 2025 and is expected to reach USD 5.92 Bn by 2032, reflecting a compound annual growth rate (CAGR) of 8.1% from 2025 to 2032. This steady growth reflects increasing demand for advanced antibiotic solutions, driven by rising incidences of multi-drug-resistant bacterial infections and expanding healthcare infrastructure worldwide.

Key Takeaways of the Ceftazidime Avibactam Market

• The Combination (CAZ/AVI) segment is expected to account for 82. 1% of the market share in 2025.
• Complicated intra-abdominal infections segment is estimated to represent 34.5% of the ceftazidime avibactam market share in 2025.
• Injectable segment is projected to capture 41.4% of the global ceftazidime avibactam market share in 2025.
• North America will dominate the ceftazidime avibactam market in 2025 with an estimated 41.2% share.
• Asia Pacific will hold 24.3% of the market share in 2025 and record the fastest growth.

Market Overview

• Market trends indicate a strong focus on innovation and development of combination therapies like ceftazidime avibactam to combat resistant pathogens.
• Moreover, increasing investments in antibiotic research, growing awareness regarding antimicrobial resistance, and favorable regulatory support are propelling market expansion.
• Adoption of these therapies in hospital settings and emerging markets further boosts growth, highlighting a shift towards targeted infection management and improved patient outcomes globally.

Current Events and Its Impact

Uncover macros and micros vetted on 75+ parameters: Get instant access to report

Segmental Insights

To learn more about this report, Download Free Sample

Why Does Combination (CAZ/AVI) Hold the Highest Share in the Global Ceftazidime Avibactam Market in 2025?

The Combination (CAZ/AVI) segment is expected to have 82.1% of market share in 2025, because there is a strong synergistic effect when ceftazidime is combined with avibactam. This combination increases the action against the resistant gram-negative pathogens and it is the therapy of choice in the world.

This combination is important as it can treat a major clinical problem by targeting successfully the multidrug-resistant Gram-negative bacteria, including bacteria that express carbapenemases and other beta-lactamases, which are the predominant mechanisms that contribute to antibiotic resistance.

Pharmaceutical companies like Zhejiang Hisun Pharmaceutical, Wockhardt, Alkem Laboratories, Lupin and Aurobindo Pharma are working on or distributing ceftazidime-avibactam preparations in the new markets. Their large-scale manufacturing, cost-efficient production, and geographical coverage offer greater access to the combination outside of the large western markets, strengthening its dominance over the market.

https://www.wockhardt.com/wp-content/uploads/2024/05/press-release-wck-5222.pdf

Ceftazidime Avibactam Market Insights, By Indication - Complicated Intra-Abdominal Infections Contribute the Highest Share Owing to High Prevalence and Challenging Treatment Complexity

The complicated intra-abdominal infections will occupy 34.5% of the market in 2025, due to the frequent occurrence of resistant Gram-negative pathogens that demand the use of potent therapy within a short period. They are severer and polymicrobial in nature, and this necessitates clinicians to use advanced BL/BLI to put high-risk patients on their feet. The increase in extended-spectrum beta-lactamase (ESBL) and carbapenemase rates and the number of post-surgical infections boost the cesftazidine avibactam use in cIAI protocols.

Hospitals focus on it as a better outcome, lesser toxicity, and reliable activity towards challenging pathogens. These infections are normally caused due to perforation of the gastrointestinal tract or post-surgical complications, which cause peritonitis and abscess, which are conditions that need high-powered antimicrobial therapy.

Injectable Segment Dominates the Global Ceftazidime Avibactam Market

Injectable is the most desired dosage form within the international ceftazidime avibactam market with an estimated 41.4% share in 2025 due to its direct arrival at the systemic circulation, which causes immediate effect of action a decisive element in the management of severe, life-threatening infections. The injectable preparations facilitate good bioavailability and accurate dosing, especially in patients who are very ill, and rapid and effective concentrations of drugs are required.

As an illustration, major manufacturers widening the availability of injectable ceftazidime avibactam comprise Zydus Lifesciences, Dr. Reddy labs, Teva Pharmaceutical industries, Baxter international, and Fresenius Kabi. Such companies promote market penetration by effective sterile-injectables production networks, hospital-based distribution, and competitive pricing, in the North American, European and emerging markets.

Pricing and Reimbursement Dynamics for Ceftazidime Avibactam

• Ceftazidime avibactam commands a premium price globally because it targets high-mortality CRE infections and replaces toxic, failure-prone regimens like colistin. Hospitals treat it as a restricted formulary drug, requiring antimicrobial stewardship approval and microbiology evidence due to its budget impact. In the U.S., reimbursement flows through bundled DRG payments, pushing hospitals to justify use with clear clinical need. In Europe, national HTA bodies negotiate discounts and tenders, often tying reimbursement to demonstrated reductions in ICU stay, mortality and downstream treatment costs.
• Price compression is expected as generics expand from 2025 onward, forcing manufacturers to compete on contracting terms, supply reliability and pharmaco-economic proof rather than innovation alone. Real-world evidence demonstrating clinical and cost benefits will become central in payer negotiations. Simultaneously, AMR-focused “pull incentives” in high-income countries may stabilize pricing for innovators while enabling tiered, access-oriented pricing for emerging markets where reimbursement is weaker and usage remains concentrated in tertiary hospitals.

Regional Insights

To learn more about this report, Download Free Sample

North America Ceftazidime Avibactam Market Analysis and Trends

The global ceftazidime avibactam market is being held at dominance in North America by the high level of healthcare infrastructure which owns a share of 41.2% in 2025, good regulatory systems and the presence of strong pharmaceutical industry. The area is also advantaged by positive government transportation policies that allow innovation and quick approvals of new antibiotics in the treatment of resistant infections. The developed system of hospitals and diagnostic centers facilitates massive usage of innovative antibiotic treatment.

Large pharmaceutical corporations, such as Pfizer and Allergan (since acquired by AbbVie) contribute greatly in this area by pumping much money to research and development of ceftazidime avibactam regimens. Also, industry/academic relations strengthen market development, and North America is one of the centers of clinical trials and post-market surveillance.

https://reference.medscape.com/drug/avycaz-ceftazidime-avibactam-999985

Asia Pacific Ceftazidime Avibactam Market Analysis and Trends

The fastest growing market in terms of share of 24.3% in 2025 is Asia Pacific with increasing cases of bacterial infections, which are resistant to ceftazidime avibactam and the rising expenditures on healthcare. The increased access to healthcare, government efforts to enhance antibiotic stewardship, and the increased awareness regarding resistant pathogens are driving market adoption.

The availability of both multinational firms as well as robust local companies like Lupin, Sun Pharma, and Cipla promotes commercialization process and distribution. Moreover, the enhancement of trade relations, such as low tariffs and simplified procedures, allow international pharmaceutical companies to enter the market easier, which helps to achieve a rapid market growth.

https://www.ciplamed.com/explore/key-trials/ceftazidime-avibactam-treatment-rationality-in-carbapenem-resistant-klebsiella-pneumoniae-infections

Ceftazidime Avibactam Market Outlook for Key Countries

What Makes the U.S. a Priority Market Driven by Strong Healthcare Systems and FDA Oversight?

The U.S. continues to be a major market for ceftazidime avibactam because of the high quality of healthcare facilities and strict regulatory conditions that are controlled by the USFDA. There is early access to novel antibiotic therapy against multi-drug-resistant infections, which is beneficial to the market.

Numerous players such as Pfizer are well-established, spearheading the clinical research and increasing product distribution throughout hospitals and specialty care facilities. In addition, the governmental initiatives put in place to fight antibiotic resistance add to the support of market development.

How is the Growing Burden of Antibiotic-Resistant Infections in India Accelerating Demand for Ceftazidime Avibactam?

The market for ceftazidime avibactam in India is growing at a high pace due to the threats of antibiotic-resistant infections as a serious threat to the overall health of the population. The initiatives taken by the government in making healthcare delivery more robust and enhancing the use of the antibiotics have boosted market receptivity. The local pharmaceutical giant companies, including Lupin and Cipla, participate in this by producing generic alternatives that are less expensive and carrying out local clinical trials.

In April 2025, doctors in India working in the field of infectious diseases reported that ceftazidime avibactam was losing its effectiveness because of uncontrolled use. As an infectious-diseases expert, Abdul Ghafur, who founded AMR Declaration Trust, had urged the Drugs Controller General of India to put in place stringent appellations to deter abuse. As he pointed out, this powerful treatment is under threat because it is becoming resistant too quickly in hospitals.

https://www.thehindu.com/sci-tech/health/experts-warn-against-overuse-of-last-line-antibiotics/article69483636.ece

Germany Ceftazidime Avibactam Market Trends

Germany still dominates the European ceftazidine avibactam market because of its developed healthcare sector and excellent regulatory control by the European Medicines Agency (EMA). The antimicrobial resistance and the investments in healthcare technology in the country encourage the use of novel antibiotics.

Various companies such as Bayer and Pfizer are key players because they are involved in constant research and also because they distribute by using well established networks of hospitals. The governmental reimbursement policies also favor access to new life-saving therapies in Germany.

China Ceftazidime Avibactam Market Trends

The ceftazidime avibactam market in China is expanding rapidly because of the increasing levels of antibiotic resistance and widespread healthcare reforms. The desire of the government to improve pharmaceutical innovation and regulatory conformity with world best practices have drawn multinational firms like Pfizer and local giants like Innovent Biologics.

Due to the growth of healthcare facilities, especially in cities, and the increased awareness of people, more intensive antibiotics will be used. Growth of the market is also boosted by trade facilitation measures and intellectual property protection.

Clinical Efficacy Benchmarking Across Key Anti–Multidrug-Resistant (MDR) Therapeutics

• Ceftazidime avibactam remains the most dependable treatment for infections caused by Klebsiella Pneumoniae Carbapenemase (KPC) and OXA-48–type carbapenemase producing Carbapenem-Resistant Enterobacterales (CRE). It consistently shows equal or better cure rates than carbapenems in complicated urinary tract infections (cUTI), complicated intra-abdominal infections (cIAI), and hospital-acquired/ventilator-associated pneumonia (HAP/VAP). It also delivers lower mortality than older colistin-based regimens. Its performance against Multidrug-Resistant Pseudomonas aeruginosa is generally strong but varies by strain, and resistance can emerge, which makes antimicrobial stewardship essential. Even with these challenges, it remains the most balanced option in terms of potency, safety, and real-world outcomes among advanced β-lactam/β-lactamase inhibitor combinations.
• Imipenem Relebactam is the closest alternative, especially for KPC-producing CRE and carbapenem-resistant Pseudomonas aeruginosa, where relebactam restores imipenem activity. However, its clinical evidence base is still smaller than that of ceftazidime avibactam. Meropenem continues to be the standard carbapenem for severe Gram-negative infections when carbapenemase enzymes are not present, but it performs poorly against true CRE. Cefiderocol, a siderophore cephalosporin, has the broadest activity against metallo-β-lactamase (MBL) producers and highly resistant non-fermenters, yet variable mortality outcomes in certain pathogens keep it mainly in a salvage-therapy role rather than a first-line competitor.

Market Players, Key Developments, and Competitive Intelligence

To learn more about this report, Download Free Sample

Key Developments

• In April 2025, the U.K. Health Security Agency warned that early signs of resistance were emerging against ceftazidime avibactam, a recently adopted NHS antibiotic. UKHSA reported low-level resistance in select clinical isolates and urged close surveillance to protect treatment effectiveness.
• In February 2024, Pfizer Inc., a global biopharmaceutical company, gained strong support from Korean infectious disease experts after the reimbursement of Zavicefta, its ceftazidime avibactam antibiotic for severe MDR infections. Specialists from Seoul St. Mary’s Hospital and Korea University Anam Hospital highlighted rising CRE cases in Korea and stressed that Zavicefta remains the only active antibiotic against these infections in the country.
• In January 2023, Alkem Laboratories, a major Indian pharmaceutical manufacturer, launched Zidavi, a ceftazidime avibactam antibiotic for MDR infections. Alkem introduced the therapy to improve access and affordability for critically ill patients in India. Zidavi is recommended by IDSA and ICMR for treating CRE infections, including KPC and OXA-48 cases. The drug is approved by U.S. FDA, EMA and CDSCO for HAP, cUTI and complicated intra-abdominal infections.

Top Strategies Followed by Global Ceftazidime Avibactam Market Players

Uncover macros and micros vetted on 75+ parameters: Get instant access to report

Market Report Scope

Ceftazidime Avibactam Market Report Coverage

Ceftazidime Avibactam Market Dynamics

To learn more about this report, Download Free Sample

Ceftazidime Avibactam Market Driver - Growing Incidence of Carbapenem-Resistant Gram-Negative Infections

The rising level of carbapenem resistance gram-negative bacterial infections is a critical consideration that is driving the need to find effective treatment alternatives like ceftazidime-avibactam. These MDR pathogens with such strains as Klebsiella pneumoniae and Pseudomonas aeruginosa present serious therapeutic challenges because of their resistance to conventional antibiotics and especially carbapenems, which are usually viewed as a last-resort medication. With the current increase in the number of such resilient infections world over, medical practitioners have been forced to identify alternative antimicrobial agents that can effectively fight complex infections. Ceftazidime-avibactam containing a novel combination of cephalosporin and beta-lactamase inhibitor has a wide spectrum of activity against resistant gram-negative bacteria, which meets an immediate unmet medical demand.

In October 2025, WHO warned that rising antibiotic resistance is accelerating worldwide, with one in six infections in 2023 already resistant to key treatments and resistance increasing 5–15% annually. The report highlighted severe resistance in Gram-negative pathogens like E. coli and K. pneumoniae, making advanced therapies such as Ceftazidime Avibactam, developed by Pfizer known for global anti-infective research, and AbbVie known for expanding anti-infective portfolios, increasingly vital as first-line options fail.

https://www.who.int/news/item/13-10-2025-who-warns-of-widespread-resistance-to-common-antibiotics-worldwide

Ceftazidime Avibactam Market Opportunity - Development of Combination Regimens for Resistant Phenotypes

The market of ceftazidime avibactam globally provides a major opportunity in the evolution of combination regimens which have specifics of the resistant bacterial phenotype. As the cases of multi-drug resistant (MDR) and extensively drug-resistant (XDR) Gram-negative infections continue to grow, the need to find effective treatment methods is growing exponentially. Having a wide range of resistant pathogens including those that produce extended-spectrum β-lactamases (ESBLs) and carbapenemases, Ceftazidime Avibactam as a powerful combination of 2 2-lactam and 2-lactamase inhibitors is effective in treating a wide range of pathogens. Nonetheless, new resistance patterns require the consideration of novel synergistic interventions with drugs to improve clinical outcomes.

For example, multiple companies are pushing combination strategies to extend ceftazidime-avibactam effectiveness against MDR and XDR pathogens. Pfizer is testing dual-antibiotic regimens for severe Gram-negative infections. Shionogi is evaluating synergistic β-lactam combinations to counter carbapenemase producers. Venatorx Pharmaceuticals is advancing next-generation β-lactam pairings for difficult CRE strains. Innoviva is assessing combination options for XDR coverage. Wockhardt is exploring multi-drug regimens targeting hospital-acquired resistant infections, while Spero Therapeutics is studying adjunct therapies that boost β-lactam activity in high-resistance settings.

Analyst Opinion (Expert Opinion)

• The market of ceftazidime avibactam is informed by the increasing rates of bacterial infection and antimicrobial resistance (AMR). Market growth is stimulated by technological progress in the development of drugs, and regulatory assistance, including fast-track approvals by the USFDA. But such issues as the cost of treatments and alternative treatment therapies still exist. The new opportunities are collaborations on research and broadening the treatment indications on resistant infections.
• Such conferences as the 2023 International Conference on Antibiotic Resistance have been instrumental in improving antibiotic innovations. Such events support the coordination of efforts of stakeholders in fighting AMR. It is markedly worth considering that a 2022 WHO pilot project focused on improving access to antibiotics in low-income nations emphasizes the increased significance of ceftazidime avibactam in terms of meeting the healthcare requirements of the global population.

Market Segmentation

• Type Insights (Revenue, USD Bn, 2020 - 2032)
  • Combination (CAZ/AVI)
  • Ceftazidime (CAZ)
  • Avibactam (AVI)
• Indication Insights (Revenue, USD Bn, 2020 - 2032)
  • Complicated intra-abdominal infections
  • Complicated urinary tract infections
  • Hospital-acquired bacterial pneumonia
  • Ventilator-associated bacterial pneumonia
  • Bloodstream infections caused by carbapenem-resistant organisms
  • Other multidrug-resistant Gram-negative infections
• Dosage Form Insights (Revenue, USD Bn, 2020 - 2032)
  • Injectable
  • Powder for Reconstitution
  • Pre-filled Syringes
• Drug Type Insights (Revenue, USD Bn, 2020 - 2032)
  • Branded
  • Generic
• End User Insights (Revenue, USD Bn, 2020 - 2032)
  • Tertiary-care hospitals
  • Secondary-care hospitals
  • Long-term acute-care facilities
  • Specialized infectious disease centers
• Distribution Channel Insights (Revenue, USD Bn, 2020 - 2032)
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• Regional Insights (Revenue, USD Bn, 2020 - 2032)
  • North America
    • U.S.
    • Canada
  • Latin America
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
  • Europe
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Middle East
    • GCC Countries
    • Israel
    • Rest of Middle East
  • Africa
    • South Africa
    • North Africa
    • Central Africa
• Key Players Insights
  • Pfizer
  • Allergan
  • AbbVie
  • Merck & Co
  • Cipla
  • Aurobindo Pharma
  • Sun Pharmaceutical Industries
  • Lupin Pharmaceuticals
  • Hikma Pharmaceuticals
  • Sandoz
  • Fresenius Kabi
  • Dr Reddy’s Laboratories
  • Zydus Lifesciences
  • Baxter International
  • Teva Pharmaceutical Industries

Sources

Primary Research Interviews

Industry Stakeholders List

• Infectious disease specialists
• Hospital pharmacy directors
• Hospital procurement managers
• Clinical microbiologists
• Antimicrobial stewardship committees
• Pharmaceutical manufacturing QC/QA heads

End Users List

• Critical care physicians
• ICU nurses
• Surgical department clinicians
• Emergency department physicians
• Home-infusion therapy providers
• Long-term care facility clinicians

Government and International Databases

• World Health Organization (WHO)
• U.S. Food and Drug Administration (FDA)
• European Medicines Agency (EMA)
• Centers for Disease Control and Prevention (CDC)
• National Health Service (NHS) Digital
• ClinicalTrials.gov

Trade Publications

• Pharmaceutical Technology
• Drug Discovery & Development
• Pharma Times
• Hospital Pharmacy Europe
• The Pharma Letter
• Fierce Pharma Manufacturing

Academic Journals

• The Lancet Infectious Diseases
• Clinical Infectious Diseases
• Antimicrobial Agents and Chemotherapy
• Journal of Antimicrobial Chemotherapy
• International Journal of Infectious Diseases
• Emerging Infectious Diseases

Reputable Newspapers

• The New York Times
• The Guardian
• Financial Times
• The Washington Post
• Reuters Health
• Bloomberg Health

Industry Associations

• Infectious Diseases Society of America (IDSA)
• American Society of Health-System Pharmacists (ASHP)
• European Society of Clinical Microbiology & Infectious Diseases (ESCMID)
• International Society of Antimicrobial Chemotherapy (ISAC)
• Pharmaceutical Research and Manufacturers of America (PhRMA)
• International Hospital Federation (IHF)

Proprietary Elements

• CMI Data Analytics Tool: Proprietary analytics tool to analyze real-time market trends, consumer behavior, and technology adoption in market
• Proprietary CMI Existing Repository of Information for Last 8 Years